Targeting proteases: successes, failures and future prospects (original) (raw)

• Puente, X. S., Sanchez, L. M., Overall, C. M. & Lopez-Otin, C. Human and mouse proteases: a comparative genomic approach. Nature Rev. Genet. 4, 544–558 (2003).
  Article CAS PubMed Google Scholar
• Rawlings, N. D., Tolle, D. P. & Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 32 (Database issue), D160–D164 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Barrett, A. J., Rawlings, N. D. & Woessner, J. F. Jr (eds) Handbook of Proteolytic Enzymes 2nd edn (Academic, Amsterdam, 2004). An essential book for every protease lab. Contains a lot of information about the majority of known proteases from various organisms.
  Google Scholar
• Davie, E. W. & Neurath, H. Identification of a peptide released during autocatalytic activation of trypsinogen. J. Biol. Chem. 212, 515–529 (1955).
  Article CAS PubMed Google Scholar
• Davie, E. W. & Ratnoff, O. D. Waterfall sequence for intrinsic blood clotting. Science 145, 1310–1312 (1964).
  Article CAS PubMed Google Scholar
• MacFarland, R. G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202, 498–499 (1964). References 4–6 are classical works describing protease activation by limited proteolysis.
  Article Google Scholar
• Lopez-Otin, C. & Overall, C. M. Protease degradomics: a new challenge for proteomics. Nature Rev. Mol. Cell Biol. 3, 509–519 (2002). A valuable collection of different approaches for system-wide analysis of proteases.
  Article CAS Google Scholar
• Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1b processing in monocytes. Nature 356, 768–774 (1992).
  Article CAS PubMed Google Scholar
• Blobel, C. P. ADAMs: key components in EGFR signalling and development. Nature Rev. Mol. Cell Biol. 6, 32–43 (2005).
  Article CAS Google Scholar
• Thomas, G. Furin at the cutting edge: from protein traffic to embryiogenesis and disease. Nature Rev. Mol. Cell Biol. 3, 756–766 (2002).
  Article CAS Google Scholar
• Weihofen, A. & Martoglio, B. Intramembrane-cleaving proteases:controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 13, 71–78 (2003).
  Article CAS PubMed Google Scholar
• Glickman, M. J. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373–428 (2002).
  Article CAS PubMed Google Scholar
• Davie, E. W., Fujikawa, K. & Kisiel, W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30, 10363–10370 (1991).
  Article CAS PubMed Google Scholar
• Koblinski, J. E., Ahram, M. & Sloane, B. F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113–135 (2000).
  Article CAS PubMed Google Scholar
• Stennicke, H. S., Ryan, C. A. & Salvesen, G. S. Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem. Sci. 27, 94–101 (2002).
  Article CAS PubMed Google Scholar
• Thome, M. et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517–521 (1997).
  Article CAS PubMed Google Scholar
• Cuconati, A. & White, E. Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev. 16, 2465–2478 (2002).
  Article CAS PubMed Google Scholar
• Gustafsson, D. et al. A new oral anticoagulant: the 50-year challenge. Nature Rev. Drug Discov. 3, 649–659 (2004).
  Article CAS Google Scholar
• Abbenante, G. & Fairlie, D. P. Protease inhibitors in the clinic. Med. Chem. 1, 71–104 (2005). An excellent collection of the current data on protease inhibitors in clinical and preclinical research.
  Article CAS PubMed Google Scholar
• Rueff, J. & Katus, H. A. New antithrombotic drugs on the horizon. Expert Opin. Investig. Drugs 12, 781–797 (2003).
  Article Google Scholar
• Hirsch, J. Current anticoagulant therapy — unmet clinical needs. Thromb. Res. 109, S1–S8 (2003).
  Article CAS Google Scholar
• Zaman, M. A., Oparil, S. & Calhoun, D. A. Drugs targeting the renin–angiotensin–aldosterone system. Nature Rev. Drug Discov. 1, 621–636 (2002).
  Article CAS Google Scholar
• Acharya, K. R., Sturrock, E. D., Riordan, J. F. & Ehlers, M. R. ACE revisited: a new target for structure-based drug design. Nature Rev. Drug Discov. 2, 891–902 (2003).
  Article CAS Google Scholar
• Natesh, R., Schwager, S. L., Sturrock, E. D. & Acharya, K. R. Crystal structure of the human angiotensin-converting enzyme–lisinopril complex. Nature 421, 551–554 (2003).
  Article CAS PubMed Google Scholar
• van Esch, J. H. et al. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 45, 120–125 (2005).
  Article CAS PubMed Google Scholar
• Georgiadis, D. et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin. Circ. Res. 93, 148–154 (2003).
  Article CAS PubMed Google Scholar
• Robl, J. A. et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 40, 1570–1577 (1997).
  Article CAS PubMed Google Scholar
• Kostis, J. B. et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. 17, 103–111 (2004).
  Article CAS PubMed Google Scholar
• Overall, C. M. & Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2, 657–672 (2002).
  Article CAS Google Scholar
• Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812 (1999).
  Article CAS PubMed Google Scholar
• Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002). An excellent critical analysis of failure of MMP inhibitors in clinical trials.
  Article CAS PubMed Google Scholar
• Neefjes, J. & Dantuma, N. P. Fluorescent probes for proteolysis: tools for drug discovery. Nature Rev. Drug Discov. 3, 58–69 (2004).
  Article CAS Google Scholar
• Baruch, A., Jeffery, D. A. & Bogyo, M. Enzyme activity — it's all about image. Trends Cell Biol. 14, 29–35 (2004).
  Article CAS PubMed Google Scholar
• Blum, G. et al. Dynamic imaging of protease activity with fluorescently quenched activity based probes. Nature Chem. Biol. 1, 203–209 (2005). A demonstration of in vivo monitoring protease activity in a living mouse, an extremely valuable technique in evaluating the physiological role of a protease in health and disease.
  Article CAS Google Scholar
• Page, I. H. & Helmer, O. M. A crystalline pressor substance (angiotonin) resulting from the interaction between renin and renin activator. J. Exp. Med. 71, 29 (1940).
  Article CAS PubMed PubMed Central Google Scholar
• Skeggs, L. T., Kahn, J. R. & Shumway, N. P. The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 103, 295–299 (1956).
  Article CAS PubMed PubMed Central Google Scholar
• Matthews, D. J. & Wells, J. A. Substrate phage: selection of protease substrates by monovalent phage display. Science 260, 1113–1117 (1993). The first report on the use of phage display for determining substrate specificity of a protease.
  Article CAS PubMed Google Scholar
• Harris, J. L., Peterson, E. P., Hudig, D., Thornberry, N. A. & Craik, C. S. Definition and redesign of the extended substrate specificity of granzyme B. J. Biol. Chem. 273, 27364–27373 (1998).
  Article CAS PubMed Google Scholar
• Harris, J. L. et al. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl Acad. Sci. USA 97, 7754–7759 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Berger, A. B., Vitorino, P. M. & Bogyo, M. Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4, 371–381 (2004).
  Article CAS PubMed Google Scholar
• Thornberry, N. A. et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. J. Biol. Chem. 272, 17907–17911 (1997). The first paper to demonstrate the power of combinatorial chemistry in defining the substrate specificity of a protease.
  Article CAS PubMed Google Scholar
• Turk, B. E., Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnol. 19, 661–667 (2001).
  Article CAS Google Scholar
• Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary b-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001). An excellent example of target validation using a mouse knockout model.
  Article CAS PubMed Google Scholar
• Gocheva, V. et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543–556 (2006). A good example how knockout mice models can be combined with a disease model in order to identify the appropriate targets.
  Article CAS PubMed PubMed Central Google Scholar
• Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. (in the press).
• Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M. & Horvitz, H. M. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1b-converting enzyme. Cell 75, 641–652 (1993).
  Article CAS PubMed Google Scholar
• McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206 (1999).
  Article Google Scholar
• Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, S. M. & Overall, C. M. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl Acad. Sci. USA 101, 6917–6922 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bredemeyer, A. J. et al. A proteomic approach for the discovery of protease substrates. Proc. Natl Acad. Sci. USA 101, 11785–11790 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Van Damme, P. et al. Caspase-specific and nonspecific in vivo protein processing during Fas-induced apoptosis. Nature Meth. 2, 771–777 (2005). This paper demonstrates the power of proteomics in determining in vivo protease substrates.
  Article CAS Google Scholar
• Medema, J. P. et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794–2804 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Reed, J. C. Apoptosis based therapies. Nature Rev. Drug Discov. 1, 111–121 (2002).
  Article CAS Google Scholar
• Eigenbrot, C. & Kirchhofer, D. New insight into how tissue factor allosterically regulates Factor VIIa. Trends Cardiovasc. Med. 12, 19–26 (2002).
  Article CAS PubMed Google Scholar
• Olson, S. T., Björk, I. & Bock, S. C. Identification of critical molecular interactions mediating heparin activation of antithrombin. Trends Cardiovasc. Med. 12, 198–205 (2002).
  Article CAS PubMed Google Scholar
• Bode, W. & Huber, R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204, 433–451 (1992).
  Article CAS PubMed Google Scholar
• Bode, W. & Huber, R. Structural basis of the endoproteinase–protein inhibitor interaction. Biochim. Biophys. Acta 1477, 241–252 (2000).
  Article CAS PubMed Google Scholar
• Turk, B., Turk, D. & Salvesen, G. S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 8, 1623–1637 (2002).
  Article CAS PubMed Google Scholar
• Giugliano, R. P. et al. Addition of a tissue-factor/factor VIIa inhibitor to standard treatments in NSTE-ACS managed with an early invasive strategy: results of the phase 2 ANTHEM-TIMI 32 double-blind randomized clinical trial. Am. Heart Assoc. Sci. Sessions Dallas, Texas, USA 13–16 Nov (2005).
• Vlasuk, G. P. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation Factor Xa. Thromb. Haemost. 70, 212–216 (1993).
  Article CAS PubMed Google Scholar
• Tuszynski, G. P., Gasic, T. B. & Gasic, G. J. Isolation and characterization of antistasin. J. Biol. Chem. 262, 9718–9723 (1987).
  Article CAS PubMed Google Scholar
• Armstrong, W. B. et al. Clinical modulation of oral leukoplakia and protease activity by Bowman–Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin. Cancer Res. 6, 4684–4691 (2000).
  CAS PubMed Google Scholar
• Chen, Y. W., Huang, S. C., Lin-Shiau, S. Y. & Lin, J. K. Bowman–Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 26, 1296–1306 (2005).
  Article CAS PubMed Google Scholar
• Weimann, L. M. Fully human therapeutic monoclonal antibodies. J. Immunother. 29, 1–9 (2005).
  Google Scholar
• Reuning, U. et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des. 9, 1529–1543 (2003).
  Article CAS PubMed Google Scholar
• Premzl, A., Zavašnik-Bergant, V., Turk, V. & Kos, J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell Res. 283, 206–214 (2003).
  Article CAS PubMed Google Scholar
• Novartis Institute for Tropical Diseases. New technologies for high-throughput screening and lead discovery of anti-viral compounds. Dengue Digest [online], (2005).
• McGovern, S. L., Helfand, B. T., Feng, B. & Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 46, 4265–4272 (2003).
  Article CAS PubMed Google Scholar
• De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Virol. 30, 115–133 (2004).
  Article CAS PubMed Google Scholar
• Rozman-Pungercˇar, J. et al. Inhibition of papain-like cysteine proteases and legumain by 'caspase-specific' inhibitors: when reaction mechanism is more important than specificity. Cell Death Diff. 10, 881–888 (2003). A good example of the selectivity problems of irreversible protease inhibitors.
  Article CAS Google Scholar
• Smyth, T. P. Substrate variants versus transition state analogues as noncovalent, reversible enzyme inhibitors. Bioorg. Med. Chem. 12, 4081–4088 (2004).
  Article CAS PubMed Google Scholar
• Thurmond, R. L. et al. Identification of a potent and selective noncovalent cathepsin S inhibitor. J. Pharmacol. Exp. Ther. 308, 268–276 (2004).
  Article CAS PubMed Google Scholar
• Altmann, E., Green, J. & Tintelnot-Blomley, M. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1′ substituents. Bioorg. Med. Chem. Lett. 13, 1997–2001 (2003).
  Article CAS PubMed Google Scholar
• Hardy, J. A. & Wells, J. A. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 14, 706–715 (2004).
  Article CAS PubMed Google Scholar
• Hardy, J. A., Lam, J., Nguyen, J. T., O'Brien, T. & Wells, J. A. Discovery of an allosteric site in the caspases. Proc. Natl Acad. Sci. USA 101, 12461–12466 (2004). Excellent work identifying the first small-molecule allosteric protease inhibitor.
  Article CAS PubMed PubMed Central Google Scholar
• Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25–35 (2004). The first report demonstrating that potentiating protease activity by inhibiting endogenous protease inhibitors by small molecules can be a useful therapeutic approach.
  Article CAS PubMed Google Scholar
• Bijnens, A. P., Gils, A., Knockaert, I., Stassen, J. M. & Declerck, P. J. Importance of the hinge region between a-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J. Biol. Chem. 275, 6375–6380 (2000).
  Article CAS PubMed Google Scholar
• Rupin, A., Martin, F., Vallez, M. O., Bonhomme, E. & Verbeuren, T. J. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of platelet-rich thrombus in rat mesenteric arterioles. Thromb. Haemost. 86, 1528–1531 (2001).
  Article CAS PubMed Google Scholar
• Stanton, A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs 3, 389–394 (2003).
  Article CAS PubMed Google Scholar
• Menard, J. et al. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 91, 330–338 (1995).
  Article CAS PubMed Google Scholar
• Nussberger, J., Wuerzner, G., Jensen, C. & Brunner, H. R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39, E1–E8 (2002).
  Article CAS PubMed Google Scholar
• Wood, J. M., Schnell, C. R., Cumin, F., Menard, J. & Webb, R. L. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and sponataneously hypertensive rats. J. Hypertens. 23, 417–426 (2005).
  Article CAS PubMed Google Scholar
• Mervaala, E. et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 35, 587–594 (2000).
  Article CAS PubMed Google Scholar
• Mentlein, R., Gallwitz, B. & Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide glucagon-like peptide-1 (7–36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829–835 (1993).
  Article CAS PubMed Google Scholar
• Kieffer, T. J., McIntosh, C. H. S. & Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585–3596 (1995).
  Article CAS PubMed Google Scholar
• Marguet, D. et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl Acad. Sci. USA 97, 6874–6879 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Nagakura, T. et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. 284, 501–506 (2001).
  Article CAS PubMed Google Scholar
• Deacon, C. F., Ahren, B. & Holst, J. J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Exp. Opin. Investig. Drugs 13, 1091–1102 (2004).
  Article CAS Google Scholar
• Nielsen, L. L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov. Today 10, 703–710 (2005).
  Article CAS PubMed Google Scholar
• Demuth, H. U., McIntosh, C. H. & Pederson, R. A. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta 1751, 33–44 (2005).
  Article CAS PubMed Google Scholar
• Augustyns, K., Van der Veken, P., Senten, K. & Haemers, A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. 12, 971–998 (2005).
  Article CAS PubMed Google Scholar
• Kim, D. et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 141–151 (2005).
  Article CAS PubMed Google Scholar
• Augeri, D. J. et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 5025–5037 (2005).
  Article CAS PubMed Google Scholar
• Moser, B., Wolf, M., Walz, A. & Loetscher, P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25, 75–84 (2004).
  Article CAS PubMed Google Scholar
• Yan, S., Marguet, D., Dobers, J., Reutter, W. & Fan, H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur. J. Immunol. 33, 1519–1527 (2003).
  Article CAS PubMed Google Scholar
• Gelb, B. D., Shi, G.-P., Chapman, H. A. & Desnick, R. J. Pycnodysostosis is caused by a deficiency of cathepsin K. Science 273, 1236–1238 (1996).
  Article CAS PubMed Google Scholar
• Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc. Natl Acad. Sci. USA 95, 13453–13458 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Gowen, M. et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654–1663 (1999).
  Article CAS PubMed Google Scholar
• Kiviranta, R. et al. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 16, 1444–1452 (2001).
  Article CAS PubMed Google Scholar
• Inaoka, T. et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. 206, 89–96 (1995).
  Article CAS PubMed Google Scholar
• Grabowska, U., Chambers, T. J. & Shiroo, M. Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Devel. 8, 619–630 (2005).
  CAS Google Scholar
• Stroup, G. B. et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16, 1739–1746 (2001).
  Article CAS PubMed Google Scholar
• Palmer, J. T. et al. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J. Med. Chem. 48, 7520–7534 (2005).
  Article CAS PubMed Google Scholar
• Turk, D., Guncˇar, G., Podobnik, M. & Turk, B. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol. Chem. 379, 137–147 (1998).
  Article CAS PubMed Google Scholar
• Misbach, M. et al. AAE581, a potent and highly specific cathepsin K inhibitor, prevents bone resorption after oral treatment in rat and monkey. Ann. Mtg Am. Soc. Bone Miner. Res. Nashville, Tennessee, USA 23–27 Sept (2005).
• Falgueyret, J. P. et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 48, 7535–7543 (2005).
  Article CAS PubMed Google Scholar
• Deaton, D. N. & Kumar, S. Cathepsin K inhibitors: their potential as anti-osteoporosis agents. Progr. Med. Chem. 42, 245–375 (2004). Excellent review paper focused on the development of cathepsin K inhibitors, which contains useful general information about medicinal chemistry.
  Article CAS Google Scholar
• Tavares, F. X., Deaton, D. N., Miller, A. B., Miller, L. R. & Wright, L. L. Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles. Bioorg. Med. Chem. Lett. 15, 3891–3895 (2005).
  Article CAS PubMed Google Scholar
• Brown, S. et al. Potent and selective mechanism-based inhibition of gelatinases. J. Am. Chem. Soc. 122, 6799–6800 (2000).
  Article CAS Google Scholar
• Krüger, A. et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 65, 3523–3526 (2005).
  Article PubMed Google Scholar
• Gu, Z. et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 6401–6408 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ikejiri, M. et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 280, 33992–34002 (2005).
  Article CAS PubMed Google Scholar
• Look, M. P. & Foekens, J. A. Clinical relevance of the urokinase plasminogen activator system in breast cancer. Acta Pathol. Microbiol. Immunol. Scand. 107, 150–159 (1999).
  Article CAS Google Scholar
• Dixon, S. C., Knopf, K. B. & Figg, W. D. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol. Rev. 53, 73–91 (2001).
  CAS PubMed Google Scholar
• Kos, J. & Lah, T. T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol. Rep. 5, 1349–1361 (1998).
  CAS PubMed Google Scholar
• Lai, W. T., Chang, C. H., Tang, Y., Bronson, R. & Tung, C. H. Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoar. Cartil. 12, 239–244 (2004).
  Article Google Scholar
• Cazzulo, J. J., Stoka, V. & Turk, V. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr. Pharm. Des. 7, 1143–1156 (2001).
  Article CAS Google Scholar
• Schechter, I. & Berger, A. On the size of the active site of proteinases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157–162 (1967).
  Article CAS PubMed Google Scholar
• Enari, M. et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43–50 (1998).
  Article CAS PubMed Google Scholar
• Rawson, R. B. et al. Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. Mol. Cell 1, 47–57 (1997).
  Article CAS PubMed Google Scholar
• Wilkinson, K. D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin. Cell. Dev. Biol. 11, 141–148 (2000).
  Article CAS PubMed Google Scholar
• Turk, D. et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J. 20, 6570–6582 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Silverman, G. A. et al. The serpins are an expanding superfamily of structurally similar but funtionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276, 33293–33296 (2001).
  Article CAS PubMed Google Scholar
• Stubbs, M. T. et al. The refined 2.4Å X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J. 9, 1939–1947 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Gomis-Ruth, F. X. et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389, 77–81 (1997).
  Article CAS PubMed Google Scholar
• Shiozaki, E. N. et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11, 519–527 (2003).
  Article CAS PubMed Google Scholar
• Deveraux, Q., Takahashi, R., Salvesen, G. S. & Reed, J. C. X-linked IAP is a direct inhibitor of cell death proteases. Nature 388, 300–304 (1997).
  Article CAS PubMed Google Scholar
• Turk, B., Turk, D. & Turk, V. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477, 98–111 (2000).
  Article CAS PubMed Google Scholar
• Bevec, T., Stoka, V., Pungercic, G., Dolenc, I. & Turk, V. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J. Exp. Med. 183, 1331–1338 (1996).
  Article CAS PubMed Google Scholar
• Nature Publishing Group. Signalling scissors: new perspectives on proteases [online], (2004).